TPM3 (Tropomyosin 3), also known as gamma-tropomyosin or Tm-4, is a 248 amino acid actin-binding protein that plays critical roles in regulating actin filament organization, stability, and function in both muscle and non-muscle cells. In neurons, TPM3 is essential for dendritic spine morphology, synaptic plasticity, axonal transport, and overall cytoskeletal integrity[1].
| Tropomyosin 3 | |
|---|---|
| Protein Name | Tropomyosin 3, γ-tropomyosin |
| Gene | TPM3 |
| UniProt ID | P06753 |
| PDB Structures | 1C1G, 2B9X |
| Molecular Weight | ~33 kDa |
| Protein Length | 248 amino acids |
| Subcellular Localization | Cytoplasm, cytoskeleton, [dendritic spines](/entities/dendritic-spines) |
| Protein Family | Tropomyosin family |
| Chromosomal Location | 1p36.22 |
Tropomyosins are a family of actin-binding proteins that regulate the organization and dynamics of actin filaments. TPM3 encodes the gamma-tropomyosin isoform, which is expressed in both muscle and non-muscle tissues with particularly high expression in neurons, skeletal muscle, and various non-muscle cells. The protein binds along the side of actin filaments, stabilizing them and regulating which accessory proteins can interact with the actin cytoskeleton[2].
In the nervous system, TPM3 is critically involved in maintaining cytoskeletal architecture in dendritic spines, regulating synaptic plasticity, and supporting axonal function. Mutations in TPM3 have been linked to congenital myopathies and amyotrophic lateral sclerosis (ALS), while altered TPM3 expression and localization are observed in Alzheimer's disease (AD) and Parkinson's disease (PD), making it an important player in neurodegenerative processes.
TPM3 exhibits the characteristic tropomyosin structure:
| Domain | Position | Function |
|---|---|---|
| N-terminus | 1-40 aa | Actin binding initiation, determines isoform specificity |
| Coiled-coil region | 41-200 aa | Dimerization, filament binding, regulatory interactions |
| C-terminus | 201-248 aa | Tropomyosin polymerization, proper alignment |
TPM3 possesses several distinctive structural features[3]:
Coiled-coil architecture: Two alpha-helices form a parallel coiled-coil structure with a hydrophobic core characterized by a heptad repeat pattern (abcdefg)n, where positions a and d are typically hydrophobic leucine, isoleucine, or valine residues.
Actin-binding surface: The inner face of the coiled-coil interacts with actin filaments along their groove, protecting the filament from depolymerization.
End-to-end polymerization: TPM3 molecules form head-to-tail dimers that polymerize along the actin filament, creating a continuous stabilizing coat.
Isoform-specific regions: The N-terminal variable region determines binding specificity for different actin filament populations.
| Tropomyosin | Gene | Expression | Function |
|---|---|---|---|
| TPM1 (α-Tm) | TPM1 | Muscle, brain | Muscle contraction, cytoskeleton |
| TPM2 (β-Tm) | TPM2 | Muscle, platelets | Muscle-specific functions |
| TPM3 (γ-Tm) | TPM3 | Neurons, muscle | Synaptic function, cytoskeletal regulation |
| TPM4 (δ-Tm) | TPM4 | Non-muscle | Cell motility, cytokinesis |
TPM3 plays multiple roles in actin cytoskeleton regulation[4]:
Filament stabilization: TPM3 binding protects actin filaments from depolymerization and fragmentation
Myosin regulation: TPM3 determines which myosin motors can bind to actin filaments—different tropomyosin isoforms create "highway" vs. "local" tracks for different myosin types
Spatial regulation: TPM3 isoforms localize to specific cellular compartments, restricting actin dynamics to particular regions
Accessory protein recruitment: TPM3 recruits regulatory proteins to actin filaments
TPM3 is essential for dendritic spine morphology and function[5]:
In axons, TPM3[6]:
TPM3 contributes to both LTP and LTD[7]:
| Region | Expression Level | Cellular Localization |
|---|---|---|
| Cerebral cortex | High | Pyramidal neurons, interneurons |
| Hippocampus | High | CA1-CA3 pyramidal cells, dentate granule cells |
| Cerebellum | Moderate | Purkinje cells |
| Brainstem | Moderate | Various nuclei |
| Spinal cord | High | Motor neurons |
TPM3 is strongly linked to ALS pathogenesis[8][9]:
In Alzheimer's disease, TPM3 alterations contribute to pathology[10]:
TPM3 is implicated in PD through multiple mechanisms:
TPM3 mutations cause several congenital myopathies[12][13]:
| Condition | Phenotype | Mechanism |
|---|---|---|
| Congenital myopathy with fiber-type disproportion | Type 1 fiber atrophy | Loss of function |
| Nemaline myopathy | Muscle weakness, nemaline rods | Dominant negative |
| Cap disease | Cap-like structures in muscle fibers | Toxic aggregates |
TPM3 interacts with multiple neurodegenerative disease proteins[11:1]:
| Approach | Mechanism | Status | Indication |
|---|---|---|---|
| Gene therapy | Deliver functional TPM3 | Research | ALS, CMT |
| Small molecule stabilizers | Enhance TPM3-actin binding | Discovery | Neurodegeneration |
| Aggregation inhibitors | Prevent TPM3 incorporation | Preclinical | AD, PD, ALS |
| Antisense oligonucleotides | Splice-switching, knock down mutant | Preclinical | ALS, myopathy |
| Partner | Interaction | Functional Significance |
|---|---|---|
| Actin | Direct binding | Filament stabilization |
| Myosin II | Regulatory | Muscle contraction |
| Myosin V | Regulatory | Dendritic transport |
| Myosin VI | Regulatory | Retrograde transport |
| Tropomodulin | Complex | Filament assembly |
| Troponin | Muscle complex | Muscle regulation |
Gunning PW, et al. Tropomyosin isoforms: determinants of actin filament localization and function. Nature Reviews Molecular Cell Biology. 2018. ↩︎
Pievey J, et al. Tropomyosin and actin: partners in crime for neuronal integrity. Trends in Neurosciences. 2019. ↩︎
Hill J, et al. Tropomyosin: structure function and interactions. FEBS Letters. 2006. ↩︎
Cooper JA, et al. Tropomyosin and actin filament dynamics. Nature Reviews Molecular Cell Biology. 2009. ↩︎
Han L, et al. Dendritic spine morphology and tropomyosin function. Cerebral Cortex. 2018. ↩︎
Schevzov G, et al. Tropomyosin localization and function in neurons. Journal of Neuroscience. 2011. ↩︎
Durrieu L, et al. Tropomyosin in synaptic plasticity and neurodegeneration. Trends in Cell Biology. 2015. ↩︎
Karkar S, et al. Tropomyosin mutations in amyotrophic lateral sclerosis. Brain. 2020. ↩︎
Lawson S, et al. TPM3 mutations in ALS: functional characterization. Nature Neuroscience. 2023. ↩︎
Goodman SR, et al. Actin cytoskeleton in Alzheimer's disease pathogenesis. Nature Reviews Neurology. 2021. ↩︎
Choi J, et al. TPM3 in tauopathies and protein aggregation. Acta Neuropathologica Communications. 2021. ↩︎ ↩︎
Nixon AB, et al. Tropomyosin mutations in congenital myopathies. Nature Reviews Neurology. 2013. ↩︎
Taylor K, et al. TPM3 mutations cause congenital myopathy with fiber-type disproportion. Nature Genetics. 2018. ↩︎